Molecular Dx Significance 7/10

Genetic and Epigenetic Landscape of Cutaneous T-Cell Lymphoma Mapped by NGS

NGS studies have revealed extensive heterogeneity across CTCL subtypes while identifying recurrent alterations in epigenetic remodelling, cell cycle regulation, and oncogenic pathway activation, with aberrant JAK-STAT signalling emerging as a common but mechanistically diverse theme. Several mutated genes represent actionable therapeutic targets, and the data are generating improved diagnostic and prognostic biomarkers. These findings provide a molecular foundation for developing subtype-specific treatment strategies in this challenging group of lymphomas.

The original study

Genetic and epigenetic insights into cutaneous T-cell lymphoma.

Authors
Tensen CP, Quint KD, Vermeer MH
Journal
Blood
Type
Journal Article, Review
PMID
34570882
Read the original study →

Original abstract

Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of non-Hodgkin T-cell lymphomas that present in the skin. In recent years, significant progress has been made in the understanding of the pathogenesis of CTCLs. Progress in CTCL classifications combined with technical advances, in particular next-generation sequencing, enabled a more detailed analysis of the genetic and epigenetic landscape and transcriptional changes in clearly defined diagnostic entities. These studies not only demonstrated extensive heterogeneity between different CTCL subtypes but also identified recurrent alterations that are highly characteristic for diagnostic subgroups of CTCLs. The identified alterations, in particular, involve epigenetic remodeling, cell cycle regulation, and the constitutive activation of targetable oncogenic pathways. In this respect, aberrant JAK-STAT signaling is a recurrent theme; however, it is not universal for all CTCLs and has seemingly different underlaying causes in different entities. A number of the mutated genes identified are potentially actionable targets for the development of novel therapeutic strategies. Moreover, these studies have produced an enormous amount of information that will be critically important for the further development of improved diagnostic and prognostic biomarkers that can assist in the clinical management of patients with CTCL. In the present review, the main findings of these studies in relation to their functional impact on the malignant transformation process are discussed for different subtypes of CTCLs.